Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers

Obesity Reviews

Volumn 10, Issue 4, 2009, Pages 412-419

  Edens, M A ^a,b   Kuipers, F ^a   Stolk, R P ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular disease; Hepatic fat

Indexed keywords

ADIPONECTIN; ATORVASTATIN; BLOOD CLOTTING FACTOR; CLOFIBRATE; CYTOKINE; FAT; FATTY ACID; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOSARTAN; METFORMIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; ROSIGLITAZONE; URSODEOXYCHOLIC ACID;

BLOOD CLOTTING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLELITHIASIS; CLINICAL TRIAL; COMORBIDITY; CYTOKINE PRODUCTION; DIET; DISEASE ASSOCIATION; DYSLIPIDEMIA; FATTY LIVER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; LAPAROSCOPIC SURGERY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; REVIEW; RISK ASSESSMENT;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FATTY LIVER; HUMANS; INSULIN RESISTANCE; OBESITY; PREVALENCE; RISK FACTORS;

EID: 67651173053     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2009.00594.x     Document Type: Review

References (80)

1. Friedman JM. Obesity in the new millennium. Nature 2000 404 : 632 634. (Pubitemid 30205067)
2. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999 341 : 1097 1105. (Pubitemid 29466221)
3. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr., Razak, F, Sharma AM, Anand SS. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005 366 : 1640 1649. (Pubitemid 41552419)
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999 116 : 1413 1419. (Pubitemid 29258890)
5. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, Schminke U, Kessler C, John U. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005 11 : 1848 1853. (Pubitemid 40520783)
6. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005 42 : 44 52. (Pubitemid 40911310)
7. Venturi C, Zoppini G, Zamboni C, Muggeo M. Insulin sensitivity and hepatic steatosis in obese subjects with normal glucose tolerance. Nutr Metab Cardiovasc Dis 2004 14 : 200 204. (Pubitemid 39462924)
8. Colicchio P, Tarantino G, del Genio F, Sorrentino P, Saldalamacchia G, Finelli C, Conca P, Contaldo F, Pasanisi F. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 2005 49 : 289 295. (Pubitemid 41291550)
9. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003 289 : 3000 3004. (Pubitemid 37430103)
10. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006 44 : 865 873. (Pubitemid 46489550)
11. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007 24 : 1 6. (Pubitemid 46103064)
12. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G. Nonalcoholic Fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005 54 : 3541 3546. (Pubitemid 43334347)
13. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A, Kato T, Okuda J, Ida K, Yoshikawa T. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007 13 : 1579 1584. (Pubitemid 46672668)
14. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005 143 : 722 728.
15. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007 13 : 3540 3553. (Pubitemid 47162261)
16. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005 54 : 303 306. (Pubitemid 40139250)
17. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002 8 : 731 737. (Pubitemid 34778727)
18. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC, Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001 34 : 1158 1163. (Pubitemid 33096588)
19. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004 40 : 46 54. (Pubitemid 38868922)
20. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005 54 : 117 121. (Pubitemid 40007229)
21. Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O, Spieth C, Weigert C, Fritsche A, Stumvoll M, Haring HU. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 2005 48 : 2282 2291. (Pubitemid 41618919)
22. Ryden M, Arner P. Tumour necrosis factor-alpha in human adipose tissue - from signalling mechanisms to clinical implications. J Intern Med 2007 262 : 431 438. (Pubitemid 47404374)
23. Lafontan M, Viguerie N. Role of adipokines in the control of energy metabolism: focus on adiponectin. Curr Opin Pharmacol 2006 6 : 580 585. (Pubitemid 44660944)
24. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003 112 : 91 100. (Pubitemid 38056380)
25. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006 6 : 1 28.
26. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 2004 40 : 185 194. (Pubitemid 38868937)
27. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005 21 : 702 707. (Pubitemid 41578647)
28. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008 103 : 1372 1379. (Pubitemid 351813900)
29. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002 252 : 283 294. (Pubitemid 35253696)
30. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 2005 25 : 1045 1050. (Pubitemid 40627853)
31. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006 49 : 755 765. (Pubitemid 43357551)
32. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006 64 : 679 683. (Pubitemid 43775007)
33. Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen AM, Fredriksson J, Yki-Jarvinen H. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004 47 : 1360 1369. (Pubitemid 39232420)
34. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III., Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr., Taubert, K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003 107 : 499 511. (Pubitemid 36158056)
35. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004 351 : 2599 2610. (Pubitemid 39628581)
36. Lizardi-Cervera J, Chavez-Tapia NC, Perez-Bautista O, Ramos MH, Uribe M. Association among C-reactive protein, Fatty liver disease, and cardiovascular risk. Dig Dis Sci 2007 52 : 2375 2379. (Pubitemid 47246489)
37. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, Honda S, Miyata S, Ijiri Y, Yamamoto J, Maeda N, Funahashi T, Kurata Y, Shimomura I, Tomiyama Y, Kanakura Y. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006 26 : 224 230. (Pubitemid 43732254)
38. Dekker JM, Funahashi T, Nijpels G, Pilz S, Stehouwer CD, Snijder MB, Bouter LM, Matsuzawa Y, Shimomura I, Heine RJ. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008 93 : 1489 1496.
39. Grefhorst A, Hoekstra J, Derks TG, Ouwens DM, Baller JF, Havinga R, Havekes LM, Romijn JA, Kuipers F. Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Am J Physiol Gastrointest Liver Physiol 2005 289 : G592 G598.
40. Gupta D, Varma S, Khandelwal RL. Long-term effects of tumor necrosis factor-alpha treatment on insulin signaling pathway in HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB. J Cell Biochem 2007 100 : 593 607. (Pubitemid 46180524)
41. Sherman ML, Spriggs DR, Arthur KA, Imamura K, Frei E III., Kufe DW. Recombinant human tumor necrosis factor administered as a 5-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988 6 : 344 350. (Pubitemid 18065941)
42. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005 25 : 1697 1703. (Pubitemid 41098943)
43. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002 87 : 3023 3028. (Pubitemid 34816338)
44. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005 48 : 634 642. (Pubitemid 40591217)
45. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008 28 : 27 38.
46. Thamer C, Machann J, Haap M, Stefan N, Heller E, Schnodt B, Stumvoll M, Claussen C, Fritsche A, Schick F, Haring H. Intrahepatic lipids are predicted by visceral adipose tissue mass in healthy subjects. Diabetes Care 2004 27 : 2726 2729. (Pubitemid 39441477)
47. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol 2007 99 : 6B 14B.
48. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002 45 : 461 475. (Pubitemid 34533825)
49. Goff DC Jr., Gerstein, HC, Ginsberg HN, Cushman WC, Margolis KL, Byington RP, Buse JB, Genuth S, Probstfield JL, Simons-Morton DG. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007 99 : 4i 20i.
50. Sparks JD, Sparks CE. Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem 1990 265 : 8854 8862.
51. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004 106 : 635 643. (Pubitemid 38797577)
52. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007 46 : 1081 1090. (Pubitemid 350144772)
53. Mitmesser SH, Carr TP. Trans fatty acids alter the lipid composition and size of apoB-100-containing lipoproteins secreted by HepG2 cells. J Nutr Biochem 2005 16 : 178 183. (Pubitemid 40312171)
54. Cali AM, Zern TL, Taksali SE, de Oliveira AM, Dufour S, Otvos JD, Caprio S. Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state. Diabetes Care 2007 30 : 3093 3098. (Pubitemid 350255255)
55. Gotto AM Jr. Triglyceride: the forgotten risk factor. Circulation 1998 97 : 1027 1028.
56. Peck-Radosavljevic M. Review article: coagulation disorders in chronic liver disease. Aliment Pharmacol Ther 2007 26 (Suppl. 1 21 28. (Pubitemid 47631866)
57. Thachil J. Relevance of clotting tests in liver disease. Postgrad Med J 2008 84 : 177 181. (Pubitemid 351600789)
58. Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005 11 : 5834 5839. (Pubitemid 41662835)
59. Ron D, Brasier AR, Habener JF. Transcriptional regulation of hepatic angiotensinogen gene expression by the acute-phase response. Mol Cell Endocrinol 1990 74 : C97 C104.
60. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, Quignard-Boulange A, Negrel R, Ailhaud G, Seydoux J, Meneton P, Teboul M. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001 15 : 2727 2729.
61. Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, Colmenero J, Nicolas JM, Jimenez W, Weich N, Gutierrez-Ramos JC, Arroyo V, Rodes J. Activated human Hepatic Stellate Cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003 125 : 117 125. (Pubitemid 36799113)
62. Silventoinen K, Magnusson PK, Neovius M, Sundstrom J, Batty GD, Tynelius P, Rasmussen F. Does obesity modify the effect of blood pressure on the risk of cardiovascular disease? A population-based cohort study of more than one million Swedish men. Circulation 2008 118 : 1637 1642.
63. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 2006 43 : 413 427. (Pubitemid 44568999)
64. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008 115 : 141 150.
65. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005 42 : 650 656. (Pubitemid 41233658)
66. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005 54 : 603 608. (Pubitemid 40322060)
67. Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, Teramo K, Yki-Jarvinen H. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003 52 : 701 707. (Pubitemid 36323577)
68. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997 27 : 103 107. (Pubitemid 27357062)
69. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991 12 : 224 229.
70. Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, Eid GM, Ramanathan R, Taylor DS, Schauer PR. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005 242 : 610 617.
71. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005 41 : 690 695. (Pubitemid 40462927)
72. Paumelle R, Staels B. Cross-talk between statins and PPAR alpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med 2008 18 : 73 78. (Pubitemid 351626602)
73. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002 287 : 360 372. (Pubitemid 34256388)
74. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007 16 : 39 46. (Pubitemid 46548588)
75. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996 23 : 1464 1467.
76. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005 100 : 1082 1090. (Pubitemid 40769045)
77. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004 53 : 2169 2176. (Pubitemid 38970772)
78. Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004 40 : 1222 1225. (Pubitemid 39425579)
79. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007 22 : 634 638. (Pubitemid 46608380)
80. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-Baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006 23 : 1143 1151. (Pubitemid 43779354)